Head to Head Analysis: Sagimet Biosciences (NASDAQ:SGMT) versus Tenaya Therapeutics (NASDAQ:TNYA)

Tenaya Therapeutics (NASDAQ:TNYA) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Insider and Institutional Ownership

90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 48.7% of Tenaya Therapeutics shares are owned by insiders. Comparatively, 14.7% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Tenaya Therapeutics and Sagimet Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-93.83%	-75.66%
Sagimet Biosciences	N/A	-39.88%	-38.40%

Volatility & Risk

Tenaya Therapeutics has a beta of 3.15, indicating that its stock price is 215% more volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 3.23, indicating that its stock price is 223% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Tenaya Therapeutics and Sagimet Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1	0	6	0	2.71
Sagimet Biosciences	1	0	6	0	2.71

Tenaya Therapeutics presently has a consensus price target of $6.25, indicating a potential upside of 228.95%. Sagimet Biosciences has a consensus price target of $25.67, indicating a potential upside of 236.83%. Given Sagimet Biosciences’ higher possible upside, analysts plainly believe Sagimet Biosciences is more favorable than Tenaya Therapeutics.

Valuation and Earnings

This table compares Tenaya Therapeutics and Sagimet Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$111.13 million	($0.96)	-1.98
Sagimet Biosciences	$2.00 million	123.90	-$45.57 million	($1.83)	-4.16

Sagimet Biosciences has higher revenue and earnings than Tenaya Therapeutics. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Sagimet Biosciences beats Tenaya Therapeutics on 6 of the 10 factors compared between the two stocks.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About Sagimet Biosciences

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.